melphalan and angiogenin

melphalan has been researched along with angiogenin* in 1 studies

Other Studies

1 other study(ies) available for melphalan and angiogenin

Article	Year
Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leukemia research, 2004, Volume: 28, Issue:3 Interleukin-18 (IL-18) plays a role in the host's response to tumours and angiogenesis. We determined serum levels of IL-18, vascular endothelial growth factor (VEGF), angiogenin (ANG), tumor necrosis factor (TNF-alpha) and CRP in 65 newly diagnosed myeloma patients. IL-18, VEGF, angiogenin, TNF-alpha and CRP were significantly higher at stage III in comparison to stages II and I. These cytokines (measured in 27 patients) significantly decreased after treatment. In survival analysis, higher levels of IL-18 were associated with a poorer prognosis. We conclude that increased serum IL-18 in myeloma patients correlates with advanced disease, increased levels of angiogenic cytokines and worse survival. Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Interleukin-18; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Prednisone; Prospective Studies; Ribonuclease, Pancreatic; Survival Analysis; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vincristine	2004

Article

Year

Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.

Leukemia research, 2004, Volume: 28, Issue:3

Interleukin-18 (IL-18) plays a role in the host's response to tumours and angiogenesis. We determined serum levels of IL-18, vascular endothelial growth factor (VEGF), angiogenin (ANG), tumor necrosis factor (TNF-alpha) and CRP in 65 newly diagnosed myeloma patients. IL-18, VEGF, angiogenin, TNF-alpha and CRP were significantly higher at stage III in comparison to stages II and I. These cytokines (measured in 27 patients) significantly decreased after treatment. In survival analysis, higher levels of IL-18 were associated with a poorer prognosis. We conclude that increased serum IL-18 in myeloma patients correlates with advanced disease, increased levels of angiogenic cytokines and worse survival.

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Interleukin-18; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Prednisone; Prospective Studies; Ribonuclease, Pancreatic; Survival Analysis; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vincristine

2004